In April 2025, the FDA issued an alert about compounded topical finasteride products. If you saw the headlines, you might have concluded that topical finasteride is dangerous. The actual data tells a far more nuanced story.
What the FDA Actually Said
The FDA's alert focused specifically on compounded topical finasteride products — not FDA-approved oral finasteride. The agency reported 32 adverse events from compounded topical finasteride sprays between 2019 and 2024. The reported side effects included sexual dysfunction, depression, and anxiety.
The FDA emphasized that compounded topical finasteride products are not FDA-approved and are regulated differently from standard medications. The alert was essentially a reminder: these products exist in a regulatory gray zone, and patients should be aware of potential risks.
The Context That Changes Everything
32 adverse events over 5 years against an unknown but likely very large user base. Topical finasteride usage has grown substantially since 2019, with multiple major telehealth platforms offering it. Even a conservative estimate of hundreds of thousands of users over that period makes 32 reports a tiny fraction.
The same side effects occur with oral finasteride — sexual dysfunction, depression, anxiety — at comparable or higher rates. The FDA's own labeling for oral Propecia lists these same adverse events.
Adverse event reporting is voluntary and unverified. FAERS reports don't confirm causation. They're raw signals, not clinical evidence. Anyone can submit a report, and no medical verification is required.
What This Means Practically
Compounded topical finasteride remains available and widely prescribed. The FDA alert did not restrict, ban, or recall any products. It was an informational notice — the regulatory equivalent of "be aware."
The practical takeaway: treat topical finasteride with the same informed-consent approach as oral finasteride. Understand the potential side effects (they're the same ones), get your prescription from a reputable provider, and report any concerning symptoms to your doctor.
What you should not do: panic, stop a treatment that's working for you based on a headline, or conclude that topical finasteride is uniquely dangerous compared to oral. The pharmacovigilance data (including the 2026 Gupta study) actually suggests topical generates fewer adverse event reports than oral across all categories.
The FDA's April 2025 alert reported 32 adverse events from compounded topical finasteride over 5 years — a tiny number relative to usage. The reported side effects (sexual dysfunction, depression, anxiety) are the same ones associated with oral finasteride. Compounded topical finasteride remains available and widely prescribed. The alert was informational, not restrictive. Get your prescription from a reputable provider, understand the side effect profile (same as oral), and don't let headlines override clinical evidence.